LY-2623091
- Generic Name
- LY-2623091
- Drug Type
- Small Molecule
- Chemical Formula
- C30H30FN5O3
- CAS Number
- 1162264-07-4
- Unique Ingredient Identifier
- 6FHZ595FNM
- Background
LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).
A Study of LY2623091 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02300259
- Locations
- πΊπΈ
Covance Clinical Research Inc, Daytona Beach, Florida, United States
A Study of How the Body Breaks Down and Eliminates LY2623091
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT02242981
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of LY2623091 in Participants With High Blood Pressure
- Conditions
- Primary Hypertension
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 304
- Registration Number
- NCT02194465
- Locations
- πΊπΈ
Cor Clinical Research LLC, Oklahoma City, Oklahoma, United States
π΅π·Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
πΊπΈMountain View Clinical Research, Inc, Greer, South Carolina, United States
A Study of LY2623091 in Male and Females With Chronic Kidney Disease
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT01427972
- Locations
- πΏπ¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa
Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01237899
- Locations
- π³π±
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zuidlaren, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.